Depending on the receptor expression and histological features, breast cancer can be divided into luminal A-like, luminal B-like HER−, luminal B-like HER+, HER2-enriched (non-luminal) and triple negative breast cancer (TNBC) that tests negative for ER, PR and HER2 [2,8]. This evidence concerns the gene ERBB2 and breast cancer.